NASDAQ
20.11.24
21:59 Uhr
8,715 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10. | Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 | 2 | GlobeNewswire (USA) | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.10. | Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.10. | Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.5% - Should You Sell? | 3 | MarketBeat | ||
| 29.08. | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | 3 | GlobeNewswire (USA) | ||
| 19.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants | 5 | GlobeNewswire (USA) | ||
| 08.08. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.08. | Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, revenue of $7.3M | 2 | Seeking Alpha | ||
| 08.08. | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | 190 | GlobeNewswire (Europe) | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| 08.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients | 12 | GlobeNewswire (USA) | ||
| 18.07. | Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients | 2 | MedCity News | ||
| 18.07. | Phathom Pharma announces Voquezna label expansion | 1 | Seeking Alpha | ||
| 18.07. | Phathom Pharma's Voquezna 10 Mg Gets FDA Approval For Non-erosive GERD | 1 | RTTNews | ||
| 18.07. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.06. | Phathom Pharmaceuticals, Inc. - 10-Q/A, Quarterly Report | 2 | SEC Filings | ||
| 14.06. | Phathom Pharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 28.05. | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,190 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,500 | -2,94 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 22,690 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,715 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
